Meeting
2022 ASCO Annual Meeting
Preoperative chemoradiation (CRT) with carboplatin (CBP)/paclitaxel (PCL) (CP) or with 5-fluorouracil (FU)/oxaliplatin (OX) (Fx) for esophageal or junctional cancer: A randomized phase 2 trial.
Authors
Antoine Adenis
Department of Medical Oncology, Montpellier Cancer Institute (ICM), Montpellier, France
Antoine Adenis , Samuel Le Sourd , Xavier Mirabel , Amaury Paumier , Emilie Bogart , Veronique Vendrely , Olivier Glehen , Laetitia Dahan , Victor Simmet , Damien Bergeat , Emmanuelle Samalin , Marion Chauvenet , Xavier Benoit d'Journo , Sandrine Hiret , Caroline Gronnier , Khémara Gnep , Marie Vanseymortier , Farid El Hajbi , Marie-Cecile Le Deley , Guillaume Piessen
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Track
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Sub Track
Esophageal or Gastric Cancer
Clinical Trial Registration Number
NCT02359968
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 4015)
DOI
10.1200/JCO.2022.40.16_suppl.4015
Abstract #
4015
Poster Bd #
3
Abstract Disclosures
Similar Posters
Poster
2018 ASCO Annual Meeting
Survival outcomes from CALGB 80803 (Alliance): A randomized phase II trial of PET scan-directed combined modality therapy for esophageal cancer.
First Author: Karyn A. Goodman
Poster
2019 ASCO Annual Meeting
Efficacy and safety of FOLFIRINOX in advanced biliary tract cancer after failure of gemcitabine plus cisplatin: A phase II trial.
First Author: Ali Belkouz
Poster
2018 ASCO Annual Meeting
Induction chemoradiotherapy for esophageal cancer: Comparing CROSS regimen with cisplatin/5-FU.
First Author: Abraham Geller
Poster
2017 ASCO Annual Meeting
Comparison of chemoradiotherapy (CRT) using carboplatin/paclitaxel (CP) versus cisplatin/5-FU (CF) for esophageal or gastroesophageal junctional (GEJ) cancer.
First Author: Hao-Wen Sim